Marker Therapeutics Inc [NASDAQ: MRKR] slipped around -0.26 points on Tuesday, while shares priced at $1.0 at the close of the session, down -20.63%.
Marker Therapeutics Inc stock is now -72.60% down from its year-to-date (YTD) trading value. MRKR Stock saw the intraday high of $1.4 and lowest of $0.975 per share. The company’s 52-week high price is 5.95, which means current price is +5.26% above from all time high which was touched on 07/17/25.
Compared to the average trading volume of 1.22M shares, MRKR reached a trading volume of 45015152 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Marker Therapeutics Inc [MRKR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRKR shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRKR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Canaccord Genuity have made an estimate for Marker Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on March 25, 2021, representing the official price target for Marker Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Cantor Fitzgerald analysts kept a Overweight rating on MRKR stock. On May 12, 2020, analysts decreased their price target for MRKR shares from 5 to 2.50.
The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 0.91.
How has MRKR stock performed recently?
Marker Therapeutics Inc [MRKR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.50. With this latest performance, MRKR shares dropped by -35.48% in over the last four-week period, additionally sinking by -33.77% over the last 6 months – not to mention a drop of -67.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRKR stock in for the last two-week period is set at 33.25, with the RSI for the last a single of trading hit 0.1413, and the three-weeks RSI is set at 0.1561 for Marker Therapeutics Inc [MRKR]. The present Moving Average for the last 50 days of trading for this stock 1.4358, while it was recorded at 1.1840 for the last single week of trading, and 1.9186 for the last 200 days.
Marker Therapeutics Inc [MRKR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Marker Therapeutics Inc [MRKR] shares currently have an operating margin of -272.41%. Marker Therapeutics Inc’s Net Margin is presently recorded at -271.11%.
Marker Therapeutics Inc (MRKR) Capital Structure & Debt Analysis
According to recent financial data for Marker Therapeutics Inc. ( MRKR), the Return on Equity (ROE) stands at -144.68%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -110.48%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Marker Therapeutics Inc’s Return on Invested Capital (ROIC) is -139.25%, showcasing its effectiveness in deploying capital for earnings.
Marker Therapeutics Inc (MRKR) Efficiency & Liquidity Metrics
Based on Marker Therapeutics Inc’s (MRKR) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Marker Therapeutics Inc (MRKR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Marker Therapeutics Inc. (MRKR) effectively leverages its workforce, generating an average of -$2922000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.45% and a Quick Ratio of 3.45%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Marker Therapeutics Inc [MRKR]
With the latest financial reports released by the company, Marker Therapeutics Inc posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.13. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRKR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Marker Therapeutics Inc go to 7.97%.
Insider trade positions for Marker Therapeutics Inc [MRKR]
There are presently around $26.32%, or 28.32%% of MRKR stock, in the hands of institutional investors. The top three institutional holders of MRKR stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 1.07 million shares, which is approximately 12.0139%. AISLING CAPITAL MANAGEMENT LP, holding 0.31 million shares of the stock with an approximate value of $$1.71 million in MRKR stocks shares; and AISLING CAPITAL MANAGEMENT LP, currently with $$1.29 million in MRKR stock with ownership which is approximately 2.6723%.
